Turning Point Brands, Inc. (TPB) Guidance & Earnings Results

On 2026-08-04 Turning Point Brands, Inc. raised guidance: "FY26 Modern Oral Gross Sales raised to $330-350M from $280-300M; Modern Oral Net Sales raised to $260-270M from $210-225M; FY26 Adjusted EBITDA…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

TPBTurning Point Brands, Inc.Follow TPB — free

Tobacco · Consumer Defensive

—

Price chart with a free account

Market cap: 1.3B
P/E TTM: 27.6
Dividend yield: 0.5%
52-week: —
Next earnings: 11 Nov, in 18 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Raised	FY26 Modern Oral Gross Sales raised to $330-350M from $280-300M; Modern Oral Net Sales raised to $260-270M from $210-225M; FY26 Adjusted EBITDA $70-90M · full year
7 May 26	Raised	FY2026 Modern Oral Gross Sales raised to $280-$300M from $220-$240M; Modern Oral Net Sales raised to $210-$225M from $180-$190M; FY2026 Adjusted EBITDA introduced at $70-$90M · full year
2 Mar 26	Raised	FY2026 Modern Oral Net Revenue guidance $180-190M
5 Nov 25	Raised	Adjusted EBITDA raised to $115-120M (from $110-114M); Modern Oral sales raised to $125-130M (from $100-110M) · full year
6 Aug 25	Raised	FY2025 Adjusted EBITDA guidance raised to $110.0-114.0M from $108.0-113.0M; FY2025 Modern Oral sales guidance raised to $100.0-110.0M from $80.0-95.0M · full year

Turning Point Brands, Inc. — questions

What guidance did Turning Point Brands, Inc. give?: On 2026-08-04: "FY26 Modern Oral Gross Sales raised to $330-350M from $280-300M; Modern Oral Net Sales raised to $260-270M from $210-225M; FY26 Adjusted EBITDA $70-90M"
When does Turning Point Brands, Inc. report earnings?: Turning Point Brands, Inc.'s next earnings report is expected on 2026-11-11.

Every figure on this page comes from Turning Point Brands, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.